Skip to main content
Shionogi & Co.,Ltd. logo

Shionogi & Co.,Ltd. — Investor Relations & Filings

Ticker · 4507 ISIN · JP3347200002 LEI · 35380049VXDTHZI3DY35 T Manufacturing
Open in API
Filings indexed 75 across all filing types
Latest filing 2026-04-27 M&A Activity
Country JP Japan
Listing T 4507

About Shionogi & Co.,Ltd.

https://www.shionogi.com/global/en/

Shionogi & Co., Ltd. is a drug discovery-based pharmaceutical company that researches, develops, manufactures, and markets a portfolio of prescription drugs, over-the-counter (OTC) products, and diagnostic reagents. The company prioritizes addressing unmet medical needs, with a significant focus on infectious diseases, including antibiotics, HIV, influenza, and COVID-19. A key strategic area is the development of solutions to combat antimicrobial resistance (AMR). Historically, the company is known for the development of Crestor, a widely used statin. Shionogi aims to provide innovative products and services to improve global health outcomes.

Recent filings

Filing Released Lang Actions
訂正臨時報告書
M&A Activity Classification · 94% confidence The document is a 臨時報告書 (extraordinary/timely report) filed under the Financial Instruments and Exchange Act disclosing the absorption‐type merger of the wholly owned subsidiary Torii Pharmaceuticals by Shionogi & Co. It provides detailed merger terms, schedules, financial and corporate information about the merging parties. This is clearly an M&A announcement and fits the definition of M&A Activity (Code: TAR).
2026-04-27 Japanese
当社の完全子会社である鳥居薬品株式会社の吸収合併（簡易合併・略式合併）に関するお知らせ
Regulatory Filings
2026-04-27 Japanese
2026年3月期 配当予想の修正（増配）に関するお知らせ
Regulatory Filings
2026-04-27 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a semi-annual report. According to the 'Certification Rule', documents that are primarily officer certifications or attestations, even if they reference a specific report type, should be classified as Regulatory Filings (RNS) rather than the report itself. H1 161
2025-11-07 Japanese
半期報告書－第161期(2025/04/01－2026/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Shionogi & Co., Ltd. with the Kanto Local Finance Bureau. It covers the interim accounting period from April 1, 2025, to September 30, 2025. It contains detailed financial statements, management analysis (MDA), and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-11-07 Japanese
訂正臨時報告書
M&A Activity Classification · 100% confidence The document is a 'Temporary Report' (臨時報告書) filed by Shionogi & Co., Ltd. with the Kanto Local Finance Bureau. It details a corporate split (absorption-type company split) involving the acquisition of the pharmaceutical business of Japan Tobacco Inc. This type of filing is a standard regulatory disclosure in Japan for significant corporate events, such as M&A or business restructuring, which falls under the 'Regulatory Filings' category as it is a specific statutory filing that does not fit into the other specialized categories like 10-K or Earnings Release.
2025-09-25 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.